149 related articles for article (PubMed ID: 36179403)
21. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
22. Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development.
Moinul M; Amin SA; Jha T; Gayen S
Eur J Med Chem; 2022 Nov; 241():114628. PubMed ID: 35944339
[TBL] [Abstract][Full Text] [Related]
23. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
[TBL] [Abstract][Full Text] [Related]
24. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.
Peng H; Dong Z; Qi J; Yang Y; Liu Y; Li Z; Xu J; Zhang JT
PLoS One; 2009 May; 4(5):e5676. PubMed ID: 19479068
[TBL] [Abstract][Full Text] [Related]
25. The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905792
[TBL] [Abstract][Full Text] [Related]
26. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
[TBL] [Abstract][Full Text] [Related]
27. Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update.
Engle K; Kumar G
Eur J Med Chem; 2022 Sep; 239():114542. PubMed ID: 35751979
[TBL] [Abstract][Full Text] [Related]
28. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
Sorf A; Hofman J; Kučera R; Staud F; Ceckova M
Biochem Pharmacol; 2018 Aug; 154():10-17. PubMed ID: 29673999
[TBL] [Abstract][Full Text] [Related]
29. Multidrug resistance reversing activity of newly developed phenothiazines on P-glycoprotein (ABCB1)-related resistance of mouse T-lymphoma cells.
Spengler G; Takács D; Horváth A; Riedl Z; Hajós G; Amaral L; Molnár J
Anticancer Res; 2014 Apr; 34(4):1737-41. PubMed ID: 24692704
[TBL] [Abstract][Full Text] [Related]
30. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
[TBL] [Abstract][Full Text] [Related]
31. Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance.
Wang JQ; Wang B; Lei ZN; Teng QX; Li JY; Zhang W; Ji N; Cai CY; Ma LY; Liu HM; Chen ZS
Eur J Pharmacol; 2019 Nov; 863():172611. PubMed ID: 31476282
[TBL] [Abstract][Full Text] [Related]
32. Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells.
Zhang DM; Li YJ; Shu C; Ruan ZX; Chen WM; Yiu A; Peng YH; Wang J; Lan P; Yao Z; Fung KP; Fu LW; Chen ZS; Ye WC
Anticancer Drugs; 2013 Jun; 24(5):441-54. PubMed ID: 23466650
[TBL] [Abstract][Full Text] [Related]
33. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
Patel A; Tiwari AK; Chufan EE; Sodani K; Anreddy N; Singh S; Ambudkar SV; Stephani R; Chen ZS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):189-99. PubMed ID: 23673445
[TBL] [Abstract][Full Text] [Related]
34. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
35. Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists.
Silbermann K; Li J; Namasivayam V; Baltes F; Bendas G; Stefan SM; Wiese M
J Med Chem; 2020 Sep; 63(18):10412-10432. PubMed ID: 32787102
[TBL] [Abstract][Full Text] [Related]
36. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
37. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
38. Computer-Aided Search for 5-Arylideneimidazolone Anticancer Agents Able To Overcome ABCB1-Based Multidrug Resistance.
Kaczor A; Szemerédi N; Kucwaj-Brysz K; Dąbrowska M; Starek M; Latacz G; Spengler G; Handzlik J
ChemMedChem; 2021 Aug; 16(15):2386-2401. PubMed ID: 33929088
[TBL] [Abstract][Full Text] [Related]
39. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.
Wang YJ; Kathawala RJ; Zhang YK; Patel A; Kumar P; Shukla S; Fung KL; Ambudkar SV; Talele TT; Chen ZS
Biochem Pharmacol; 2014 Aug; 90(4):367-78. PubMed ID: 24937702
[TBL] [Abstract][Full Text] [Related]
40. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
